Urea glucokinase activators
View Patent ↗The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
1. A compound having the formula:
wherein
R 3 is selected from the group consisting of phenoxy and benzyloxy, each of which is optionally substituted with one or more substituents independently selected from R 12 ;
R 12 is F, Cl, Br, —CF 3 , —CN, methyl, ethyl, isopropyl, tert-butyl, methoxy, methylthio, ethoxy, cyclopropyl-methoxy, —NHC(O)CH 3 , or —S(O) 2 —CH 3 ;
R 30 is methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, benzyloxy, or cyclopropyl-methoxy, each of which is optionally substituted with one or more substituents independently selected from R 12 ;
A is
R 8 is methylthio, isopropylthio, ethylthio, or 2-methylpropylthio, each of which is substituted with one or more substituents independently selected from R 34 ; R 34 is carboxy;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 12 is F, Cl, Br, methyl, or ethyl.
3. The compound of claim 1 , wherein R 30 is methyl or ethyl.
4. A compound, wherein the compound is
2-{2-[3-[2-(2-Chloro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid;
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , wherein the compound is 2-{2-[3-[2-(2-Chloro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid.
6. A compound, wherein the compound is
2-{2-[3-[2-(2-Fluoro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid;
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6 , wherein the compound is 2-{2-[3-[2-(2-Fluoro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid.
8. A pharmaceutical composition comprising a compound according to any one of the claims 1 to 7 and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8 , wherein the composition is in a unit dosage form comprising from about 0.05 mg to about 1000 mg of the compound according.
10. The pharmaceutical composition of claim 9 , wherein the unit dosage form comprises from about 0.1 mg to about 500 mg of the compound.
11. The pharmaceutical composition of claim 10 , wherein the unit dosage form comprises from about 0.5 mg to about 200 mg of the compound.
12. A method of treating type 2 diabetes in a human, comprising administering to said human a compound selected from the group consisting of:
2-{2-[3-[2-(2-Chloro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid; and
2-{2-[3-[2-(2-Fluoro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid;
or a pharmaceutically acceptable salt thereof.
13. A method of lowering blood glucose levels in a human, comprising administering to said human a compound selected from the group consisting of:
2-{2-[3-[2-(2-Chloro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid; and
2-{2-[3-[2-(2-Fluoro-benzyloxy)-ethyl]-3-(4-trans-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid;
or a pharmaceutically acceptable salt thereof.